Resources Press News Resources Webinars Events July 8, 2026 Notice of Office Closure GeneDesign, Inc. – Osaka SiteRead more June 23, 2026 Notice of Appointment of Directors GeneDesign, Inc. – Osaka SiteRead more April 21, 2026 Impact of the Current Situation in the Middle East on Our Manufacturing Operations GeneDesign, Inc. – Osaka SiteRead more April 16, 2026 Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing Read more March 31, 2026 NJ Bio, Inc. and Ajinomoto Bio‑Pharma Services Enter into Collaboration to Strengthen Support for Antibody–Drug Conjugate Development Read more March 2, 2026 Notice of Office Closure GeneDesign, Inc. – Osaka SiteRead more November 27, 2025 Notice of Office Closure GeneDesign, Inc. – Osaka SiteRead more November 17, 2025 Ajinomoto Bio-Pharma Services Wins “Best ADC Preclinical Publication 2024” Award for AJICAP® Technology at 2025 World ADC Awards Read more October 31, 2025 Ajinomoto Co., Inc. Enters Licensing Agreement with Astellas Pharma Inc. for Biopharmaceutical Development and Manufacturing Technology Read more October 28, 2025 Ajinomoto Bio-Pharma Services and Olon S.p.A. Form Strategic Partnership to Advance Large-Scale Peptide and Protein Manufacturing Read more October 21, 2025 Ajinomoto Bio-Pharma Services and Gene Tools Announce Collaboration to Expand Access to PMO Therapeutics Read more May 6, 2025 Successful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research by Ajinomoto Co., Inc. and RIBOMIC Inc. Read more Loading…Load More July 31, 2026 CDMOs Forge Links to Next-Gen Antibody Conjugates July 31, 2026 Manufacturing Materials for Clinical Trials – An Interview July 31, 2026 Speeding Development and Manufacturing of Materials for Clinical Trials – An Interview July 31, 2026 Emphasizing Sustainability in Contract Manufacturing – An Interview July 31, 2026 Panel Discussion – Part III: CDMO Strategy in a COVID-19 World July 31, 2026 Application of Native Ion Exchange Mass Spectrometry to Intact and Subunit Analysis of Site-Specific Antibody–Drug Conjugates Produced by AJICAP First Generation Technology July 31, 2026 Interview – A CDMO for the Future: Adapting Services for Evolving Needs July 31, 2026 Good Manufacturing Practice Strategy for Antibody–Drug Conjugate Synthesis Using Site-Specific Chemical Conjugation: First-Generation AJICAP July 31, 2026 Contract Pharma’s 20th Anniversary Retrospective Loading…Load More August 4, 2026 S-TuD Read more August 4, 2026 Our Platfom Technologies and CDMO Capabilities Read more August 4, 2026 Oligonucleotide CDMO services overview Read more August 4, 2026 miRNA mimic Read more August 4, 2026 CpG-ODN (TLR 9 Ligand) reagent Read more July 31, 2026 AJICAP Site-Selective Conjugation Technology See the AJICAP site-selective conjugation technology in actionRead more July 16, 2026 HPAPI Containment Excellence: Q&A Read more July 7, 2026 Containment Excellence in HPAPI Manufacturing: A Lifecycle Approach Read more July 23, 2024 Exploring Oligos and Peptides for Pharma Manufacturing Read more July 2, 2024 Identify the Production Strategy Best Suited for Your Protein or Peptide Read more July 2, 2024 Rethinking Traditional Manufacturing Processes to Identify Green Opportunities Read more May 23, 2024 Q&A: Building Towards A Greener Future By Implementing Sustainable Manufacturing Practices Read more Loading…Load More November 18, 2025 Webinar – Engineering the Future of API Manufacturing: A Scientific Approach to Continuous Flow July 3, 2024 Webinar – You Had Me At Flow: The Shift From Batch To Continuous March 13, 2024 Webinar – Breaking Bad Manufacturing Habits: Strategies For Sustainable API Production November 28, 2023 Plasmid Production: The Benefits of Working with an Experienced CDMO May 9, 2023 Strategies for Scaling HPAPI Production Webinar December 5, 2022 Sustainable Approaches to Oligonucleotide Manufacturing January 10, 2022 The Paradigm Shift to Continuous Flow Processes: A Holistic View May 12, 2021 Plasmid Manufacturing for Gene Therapies: An Outsourcing Partnership Duration January 28, 2021 Oligonucleotide Therapeutics: Bridging from Research to Commercial Loading…Load More August 4, 2026 Oligonucleotide-Based Therapeutics Conference August 4, 2026 The Bioprocessing Summit 2026